On behalf of Africa.com, Policy Cures Research (PCR), and Global Health Strategies (GHS), we want to share some key insights from our recent media roundtable on the newly launched Policy Cures Research – PCR Report: The Impact of Global Health R&D: The High Return of Investing in R&D for Neglected Diseases.
Introduction
As global health challenges continue to evolve, the Policy Cures Research (PCR) report provides a crucial analysis of the return on investment (ROI) from over two decades of research and development (R&D) in neglected diseases. This report highlights the profound impact of these investments on health outcomes, economic growth, and societal well-being, focusing on Sub-Saharan Africa. As we discuss these findings, we call on the media to play a pivotal role in amplifying these insights, helping us to reach decision-makers and stakeholders across the continent.
Key Findings
- Transformational Health Impact:
- 40.7 million Lives Saved: Between 2000 and 2040, R&D investments are projected to save 40.7 million lives globally, most of which are saved in Sub-Saharan Africa.
- 2.83 billion DALYs Averted: The burden of neglected diseases is significantly reduced, with 2.83 billion Disability-Adjusted Life Years (DALYs) averted due to these investments.
- Economic and Societal Gains:
- $405 ROI for Every $1 Invested: Global health R&D delivers a remarkable return, generating $405 in societal and economic benefits for every dollar invested.
- $269.8 Billion in Economic Benefits: The economic impact of improved health outcomes is substantial, with $269.8 billion in global benefits, particularly through reduced illness-related costs and increased productivity in Africa.
- Accrued Benefits to Africa:
- Africa at the Forefront: Sub-Saharan Africa stands to gain the most, with 75% of lives saved and 81% of DALYs averted in the region. By 2040, 83% of global cases of neglected diseases are expected to be averted in Africa.
- Economic Empowerment: These investments are not only saving lives but also driving economic growth, enhancing healthcare capacity, and empowering local researchers and communities.
Strategic Policy Directions
- Collaborative Financing: Foster partnerships in Africa to explore innovative and sustainable funding models for R&D, ensuring long-term support for health innovation.
- Diversified Investment: Focus on a diverse portfolio of health technologies to maximise impact and mitigate risks in African contexts.
- Streamlined Approvals: Accelerate regulatory processes and access pathways in Africa to quickly bring life-saving innovations to market.
- Impact Assessment: Prioritize rigorous impact assessments to demonstrate the effectiveness of R&D investments and guide future policy and funding decisions in Africa.
- R&D and Access Integration: Ensure that product development is closely aligned with strategies to improve healthcare access, ensuring innovations reach the people who need them most in Africa.
Call to Action for the Media and our Partners
As influential storytellers, the media has a critical role in disseminating these findings to policymakers, funders, and the broader public. By highlighting this report’s evidence and successes, journalists can drive conversations prioritising R&D investment in neglected diseases, particularly in Africa. The media’s engagement is essential to ensuring that these impactful findings inform decision-making processes, leading to sustained and increased funding for global health R&D.
Conclusion
The PCR report offers a compelling narrative of how sustained investment in global health R&D can transform lives, economies, and societies, especially in Africa. As we move forward, the media’s role in amplifying these messages will be crucial in shaping a future where health innovations continue to deliver significant returns for all. We urge journalists to take these insights forward, ensuring they reach the decision-makers who can drive positive change on the continent.